▶ IGF-1 LR3 · SUBTOPIC · MECHANISM
IGF-1 LR3 Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Long R3 Insulin-like Growth Factor 1 · 83-residue synthetic analog of native IGF-1 with N-terminal 13-residue extension and Arg substitution at position 3. Engineered to reduce IGFBP binding · extends plasma half-life from ~10 min (native) to ~6 hr (LR3).
PHARMACOKINETIC HALF-LIFE
Reported half-life for IGF-1 LR3: ~6 hours (vs ~10 minutes native IGF-1). Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
MECHANISM CATEGORIES
IGF-1 LR3 is tagged in 2 mechanism categories on GIGARESEARCH. Each category aggregates the broader pharmacology of related compounds.
The growth hormone axis is regulated by two complementary upstream signals: GHRH (stimulatory, from the hypothalamus, acting on the GHRH receptor on pituitary somatotrophs) and ghrelin (stimulatory, from the stomach, acting on the GHS-R1a). Research peptides target both arms: tesamorelin and CJC-1295 (GHRH analogs); ipamorelin, GHRP-6, and hexarelin (ghrelin-receptor agonists).
Compounds acting on metabolic regulation include incretin agonists (GLP-1, GIP, glucagon), AMPK activators (MOTS-c), and GHRH analogs that drive lipolysis (tesamorelin). The shared therapeutic target is metabolic dysfunction underlying obesity, type 2 diabetes, NAFLD, and the broader cardiometabolic syndrome.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with GIGARESEARCH evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Tomas et al. 1993 reported increased protein synthesis in rat skeletal muscle with LR3-IGF-1 administration.
Walton et al. 1995 characterized 6-hour vs 10-minute half-life · the engineering goal of the LR3 modification.
No completed human Phase 3 trials. Community-reported research protocols only.
MECHANISM Q+A
▶ What is IGF-1 LR3?
IGF-1 LR3 (Long R3 Insulin-like Growth Factor 1) is an 83-residue synthetic analog of native IGF-1 with an N-terminal 13-residue extension and an arginine substitution at position 3. The modifications reduce binding to IGF-binding-proteins (IGFBPs), extending plasma half-life dramatically.
▶ Why is IGF-1 LR3 half-life longer than native IGF-1?
Native IGF-1 is rapidly cleared due to high-affinity binding by IGFBP-3 and other IGFBPs. The Arg-substitution at position 3 in LR3 significantly reduces IGFBP binding, leaving more free IGF-1 available for receptor engagement. Half-life extends from ~10 minutes (native) to ~6 hours (LR3).
▶ IGF-1 LR3 vs growth hormone · what's different?
Growth hormone (GH) is the upstream pituitary hormone. IGF-1 is the downstream effector produced primarily by the liver in response to GH. LR3-IGF-1 bypasses the GH-axis and directly engages the IGF-1 receptor · producing IGF-1-receptor effects without the broader pleiotropic GH effects.
▶ Side effects of IGF-1 LR3?
Hypoglycemia is the most acute concern · at higher doses LR3 binds the insulin receptor with sufficient affinity to lower blood glucose. Theoretical concerns with chronic high-dose use include organ enlargement and exacerbation of active malignancy via IGF-1 axis growth signaling.
▶ Why is IGF-1 LR3 sometimes confused with IGF-1 DES?
Both are modified IGF-1 analogs. LR3 has an N-terminal extension that reduces IGFBP binding (long half-life). DES has the opposite · a tripeptide deletion at the N-terminus that also reduces IGFBP binding but with different receptor-affinity profile and shorter half-life. They are distinct compounds.
CITED LITERATURE
- Tomas FM, Knowles SE, Owens PC, et al.. Long-R3-IGF-I increases protein synthesis in rat skeletal muscle. J Endocrinol 1993. link
- Walton PE, Dunshea FR, Ballard FJ. Pharmacokinetics of LR3-IGF-I in lambs. J Endocrinol 1995. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19